trial · primary record
Biopsy Procedure
Advanced Malignant Solid Neoplasm
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 54 |
| Primary completion | 2027-05-06 |
| Primary endpoint | Number of Patients With Dose Limiting Toxicities as a Measure of Safety Profile to Determine the Recommended Phase 2 Dose (RP2D). |
| Registry ID | NCT04317105 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:33:08.805Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04317105
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.